Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies

Pharmacoepidemiol Drug Saf. 2023 Jan;32(1):9-18. doi: 10.1002/pds.5547. Epub 2022 Oct 20.

Abstract

Pharmacoepidemiology has an increasingly important role in informing and improving clinical practice, drug regulation, and health policy. Therefore, unrecognized biases in pharmacoepidemiologic studies can have major implications when study findings are translated to the real world. We propose a simple taxonomy for researchers to use as a starting point when thinking through some of the most pervasive biases in pharmacoepidemiology. We organize this discussion according to biases best assessed with respect to the study population (including confounding by indication, channeling bias, healthy user bias, and protopathic bias), the study design (including prevalent user bias and immortal time bias), and the data source (including misclassification bias and missing data/loss to follow up). This tutorial defines, provides a curated list of recommended references, and illustrates through relevant case examples these key biases to consider when planning, conducting, or evaluating pharmacoepidemiologic studies.

Keywords: biases; channeling bias; healthy user bias; immortal time bias; prevalent user bias; protopathic bias; review.

MeSH terms

  • Bias
  • Health Policy
  • Humans
  • Pharmacoepidemiology* / methods
  • Research Design*